Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 316

The DOI matches its Crossref record; 389 of the 389 references it cites were found in a registry or an index.

Platelets and cancer: a casual or causal relationship: revisited

Open access
Menter, David G., Tucker, Stephanie C., Kopetz, Scott, Sood, Anil K., Crissman, John D., Honn, Kenneth V.·2014·Cancer and Metastasis Reviews

Abstract

Human platelets arise as subcellular fragments of megakaryocytes in bone marrow. The physiologic demand, presence of disease such as cancer, or drug effects can regulate the production circulating platelets. Platelet biology is essential to hemostasis, vascular integrity, angiogenesis, inflammation, innate immunity, wound healing, and cancer biology. The most critical biological platelet response is serving as “First Responders” during the wounding process. The exposure of extracellular matrix proteins and intracellular components occurs after wounding. Numerous platelet receptors recognize matrix proteins that trigger platelet activation, adhesion, aggregation, and stabilization. Once activated, platelets change shape and degranulate to release growth factors and bioactive lipids into the blood stream. This cyclic process recruits and aggregates platelets along with thrombogenesis. This process facilitates wound closure or can recognize circulating pathologic bodies. Cancer cell entry into the blood stream triggers platelet-mediated recognition and is amplified by cell surface receptors, cellular products, extracellular factors, and immune cells. In some cases, these interactions suppress immune recognition and elimination of cancer cells or promote arrest at the endothelium, or entrapment in the microvasculature, and survival. This supports survival and spread of cancer cells and the establishment of secondary lesions to serve as important targets for prevention and therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10555-014-9498-0

Cites

389 of 389 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 389 references

Research works printed but not linked: 152

  1. Rados, C. (2004). Beyond bloodletting: FDA gives leeches a medical makeover. FDA Consumer, 38(5), 9.
  2. Winkel, R., Tajsic, N., Husum, H., Schlageter, M., Hanebuth, G., & Hoffmann, R. (2013). Saphenous perforator flap. Operative Orthopädie und Traumatologie, 25(2), 152–161. · doi:10.1007/s00064-012-0198-z
  3. Steinhubl, S. R. (2011). Historical observations on the discovery of platelets, platelet function testing and the first antiplatelet agent. Current Drug Targets, 12(12), 1792–1804. · doi:10.2174/138945011797635858
  4. Addison, W. (1842). On the colourless corpuscles and on the molecules and cytoblasts in the blood. London Med Gaz, 30, 144–152.
  5. Schultze, M. (1865). Ein heizbarer Objecttisch und seine Verwendung bei Untersuchungen des Blutes. Arch Mikrosc Anatomy, 1, 1–42. · doi:10.1007/bf02961404
  6. de Gaetano, G. (2001). A new blood corpuscle: an impossible interview with Giulio Bizzozero. Thrombosis and Haemostasis, 86(4), 973–979.
  7. Bizzozero, G. (1869). Sul midollo delle ossa. Napoli: Tipografia Italiana.
  8. Osler, W., & Schäfer, E. A. (1873). über einige im Blute vorhandene bacterienbildende Massen. Centralbl Medicine Wissensch, 11, 577–578.
  9. Howell, W. H. (1890). Observations upon the occurrence, structure, and function of the giant cells of the marrow. Journal of Morphology, 4, 117–130. · doi:10.1002/jmor.1050040106
  10. Wright, J. H. (1910). The histogenesis of blood platelets. Journal of Morphology, 21, 263–278. · doi:10.1002/jmor.1050210204
  11. Nakeff, A., & Maat, B. (1974). Separation of megakaryocytes from mouse bone marrow by velocity sedimentation. Blood, 43(4), 591–595. · doi:10.1182/blood.v43.4.591.591
  12. Pease, D. C. (1956). An electron microscopic study of red bone marrow. Blood, 11(6), 501–526. · doi:10.1182/blood.v11.6.501.501
  13. Bariety, M. (1947). Trousseau, 1801–1867 (pp. 234–235). Geneva: Mazenod.
  14. Osler, W., & McCrae, T. (1900). Latent cancer of the stomach. Phil Medical Journal, 5, 245.
  15. Henderson, P. H., Jr. (1955). Multiple migratory thrombophlebitis associated with ovarian carcinoma. American Journal of Obstetrics and Gynecology, 70(2), 452–453. · doi:10.1016/s0002-9378(16)37699-2
  16. Jarniou, A. P., & Moreau, A. (1959). Recurrent & migratory thrombophlebitis revealing a secondary cancer with mediastino-pulmonary form. Presse Médicale, 67(27), 1117–1118.
  17. Jennings, W., & Russel, W. (1948). Phlebothrombosis associated with mucin-producing carcinomas of the tail and body of the pancreas. Archives of Surgery, 56, 186–198. · doi:10.1001/archsurg.1948.01240010191009
  18. Kenney, W. (1943). The association of carcinoma in the body and tail of the pancreas with multiple venous thrombi. Surgery, 14, 600–609.
  19. Linquette, M., Mesmacque, R., Fossati, P., Luez, G., & Beghin, B. (1964). Recurrent and migratory venous thromboses. Prog ress in Medical (Paris), 92, 689–698.
  20. Mainoli, S., & Piccinelli, O. (1956). Migratory thrombophlebitis and malignant tumors; migratory thrombophlebitis occurring during two cases of reticulosarcoma. La Riforma Medica, 70(46), 1330–1334.
  21. Picard, R., Horeau, J., Guillon, J., & Robin, C. (1959). Migratory thrombophlebitis & bronchopulmonary cancer. Bulletins et Mémoires de la Société Médicale des Hôpitaux de Paris, 75(9–11), 327–329.
  22. Popesco, I., & Ciobanu, V. (1958). Migratory thrombophlebitis as a manifestation of visceral cancer. La Semaine des Hôpitaux, 34(1), 26–30.
  23. Rizzo, J. A. (1956). Migratory thrombophlebitis and visceral cancer. Revista de la Asociación Médica Argentina, 70(825–826), 236–238.
  24. Womack, W. S., & Castellano, C. J. (1952). Migratory thrombophlebitis associated with ovarian carcinoma. American Journal of Obstetrics and Gynecology, 63(2), 467–469. · doi:10.1016/s0002-9378(15)32851-9
  25. Brugarolas, A., Elias, E. G., Takita, H., Mink, I. B., Mittelman, A., & Ambrus, J. L. (1973). Blood coagulation and fibrinolysis in patients with carcinoma of the lung. Journal of Medicine, 4(2), 96–105.
  26. Peterson, H. I., Appelgren, K. L., & Rosengren, B. H. (1969). Fibrinogen metabolism in experimental tumours. European Journal of Cancer, 5(6), 535–542. · doi:10.1016/0014-2964(69)90001-2
  27. Peterson, H. I., Appelgren, K. L., & Rosengren, B. H. (1972). Experimental studies on the mechanisms of fibrinogen uptake in a rat tumour. European Journal of Cancer, 8(6), 677–681. · doi:10.1016/0014-2964(72)90151-x
  28. Gastpar, H. (1973). Inhibition of “cancer cell stickiness” through bencylan-hydrogen fumarate (fluditate). Fortschritte der Medizin, 91(33), 1322–1328.
  29. Hilgard, P. (1973). The role of blood platelets in experimental metastases. British Journal of Cancer, 28(5), 429–435. · doi:10.1038/bjc.1973.168
  30. Warren, B. A. (1973). Environment of the blood-borne tumor embolus adherent to vessel wall. Journal of Medicine, 4(3), 150–177.
  31. Warren, B. A., & Vales, O. (1972). The adhesion of thromboplastic tumour emboli to vessel walls in vivo. British Journal of Experimental Pathology, 53(3), 301–313.
  32. Cliffton, E. E., & Grossi, C. E. (1956). Effect of human plasmin on the toxic effects and growth of blood borne metastatis of the Brown-Pearce carcinoma and the V2 carcinoma of rabbit. Cancer, 9(6), 1147–1152. · doi:10.1002/1097-0142(195611/12)9:6<1147::aid-cncr2820090613>3.0.co;2-u
  33. Johnson, J. H., & Woods, J. R. (1963). An in vitro study of fibrinolytic agents on V2 carcinoma cells and intravascular thrombi in rabbits. Bulletin of the Johns Hopkins Hospital, 113, 335–346.
  34. Pearce, L., & Brown, W. H. (1923). Studies based on a malignant tumor of the rabbit: V. Metastases. Part 1. Description of the lesions with especial reference to their occurrence and distribution. The Journal of Experimental Medicine, 38(4), 347–366. · doi:10.1084/jem.38.4.347
  35. Woods, J. R. (1964). Experimental studies of the intravascular dissemination of ascitic V2 carcinoma cells in the rabbit, with special reference to fibrinogen and fibrinolytic agents. Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften, 20, 92–121.
  36. Fidler, I. J. (1970). Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. Journal of the National Cancer Institute, 45(4), 773–782.
  37. Honn, K. V., Menter, D., Cavanaugh, P. G., Neagos, G., Moilanen, D., Taylor, J. D., et al. (1983). A review of prostaglandins and the treatment of tumor metastasis. Acta Clinica Belgica, 38(1), 53–67. · doi:10.1080/22953337.1983.11718906
  38. Menter, D. G., Harkins, C., Onoda, J., Riorden, W., Sloane, B. F., Taylor, J. D., et al. (1987). Inhibition of tumor cell induced platelet aggregation by prostacyclin and carbacyclin: an ultrastructural study. Invasion & Metastasis, 7(2), 109–128.
  39. Cavanaugh, P. G., Sloane, B. F., Bajkowski, A. S., Gasic, G. J., Gasic, T. B., & Honn, K. V. (1983). Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles. Clinical & Experimental Metastasis, 1(4), 297–307. · doi:10.1007/bf00121192
  40. Menter, D. G., Hatfield, J. S., Harkins, C., Sloane, B. F., Taylor, J. D., Crissman, J. D., et al. (1987). Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells. Clinical & Experimental Metastasis, 5(1), 65–78. · doi:10.1007/bf00116627
  41. Sloane, B. F., Rozhin, J., Hatfield, J. S., Crissman, J. D., & Honn, K. V. (1987). Plasma membrane-associated cysteine proteinases in human and animal tumors. Experimental Cell Biology, 55(4), 209–224.
  42. White, J. G. (1967). A simple method for preservation of fine structure in blood cells. Thrombosis et Diathesis Haemorrhagica, 18(3–4), 745–753.
  43. White, J. G., & Krivit, W. (1967). The canalicular system of blood platelets: apossible sarcoplasmic reticulum. The Journal of Laboratory and Clinical Medicine, 49, 60.
  44. White, J. G., & Krivit, W. (1967). Changes in platelet microtubules and granules during early clot development. Thrombosis et Diathesis Haemorrhagica. Supplementum, 26, 29–42.
  45. Grossi, I. M., Fitzgerald, L. A., Kendall, A., Taylor, J. D., Sloane, B. F., & Honn, K. V. (1987). Inhibition of human tumor cell induced platelet aggregation by antibodies to platelet glycoproteins Ib and IIb/IIIa. Proceedings of the Society for Experimental Biology and Medicine, 186(3), 378–383. · doi:10.3181/00379727-186-3-rc1
  46. Vitrat, N., Letestu, R., Masse, A., Lazar, V., Vainchenker, W., & Debili, N. (2000). Thromboxane synthase has the same pattern of expression as platelet specific glycoproteins during human megakaryocyte differentiation. Thrombosis and Haemostasis, 83(5), 759–768. · doi:10.1055/s-0037-1613905
  47. Hussein, K., Dralle, W., Theophile, K., Kreipe, H., & Bock, O. (2009). Megakaryocytic expression of miRNA 10a, 17-5p, 20a and 126 in Philadelphia chromosome-negative myeloproliferative neoplasm. Annals of Hematology, 88(4), 325–332. · doi:10.1007/s00277-008-0602-9
  48. Lin, J., & Zhan, R. (2011). Advance of studies on role of miRNA in hematopoietic regulation and myeloproliferative neoplasms. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 19(4), 1071–1074.
  49. Kaushansky, K. (1994). The mpl ligand: molecular and cellular biology of the critical regulator of megakaryocyte development. Stem Cells, 12(Suppl 1), 91–96. discussion 96-97.
  50. Neumann, T. A., & Foote, M. (2000). Megakaryocyte growth and development factor (MGDF): an Mpl ligand and cytokine that regulates thrombopoiesis. Cytokines, Cellular & Molecular Therapy, 6(1), 47–56. · doi:10.1080/13684730050515912
  51. Dong-Feng, Z., Ting, L., Yong, Z., Cheng, C., Xi, Z., & Pei-Yan, K. (2013). The TPO/c-MPL pathway in the bone marrow may protect leukemia cells from chemotherapy in AML patients. Pathology and Oncology Research. doi: 10.1007/s12253-013-9696-z . · doi:10.1007/s12253-013-9696-z
  52. Cosgrove, L. J., Sandrin, M. S., Rajasekariah, P., & McKenzie, I. F. (1986). A genomic clone encoding the alpha chain of the OKM1, LFA-1, and platelet glycoprotein IIb-IIIa molecules. Proceedings of the National Academy of Sciences of the United States of America, 83(3), 752–756. · doi:10.1073/pnas.83.3.752
  53. Fitzgerald, L. A., Poncz, M., Steiner, B., Rall, S. C., Jr., Bennett, J. S., & Phillips, D. R. (1987). Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein IIb. Biochemistry, 26(25), 8158–8165. · doi:10.1021/bi00399a021
  54. Lanza, F., Kieffer, N., Phillips, D. R., & Fitzgerald, L. A. (1990). Characterization of the human platelet glycoprotein IIIa gene. Comparison with the fibronectin receptor beta-subunit gene. The Journal of Biological Chemistry, 265(30), 18098–18103. · doi:10.1016/s0021-9258(17)44722-3
  55. Miyazaki, H. (1996). Physiologic role of TPO in thrombopoiesis. Stem Cells, 14(Suppl 1), 133–138. · doi:10.1002/stem.5530140717
  56. Monzen, S., Takahashi, K., Yoshino, H., Kasai-Eguchi, K., & Kashiwakura, I. (2011). Terminal maturation of megakaryocytes and platelet production by hematopoietic stem cells irradiated with heavy-ion beams. Radiation Research, 176(1), 8–16. · doi:10.1667/rr2392.1
  57. Wang, W., Gilligan, D. M., Sun, S., Wu, X., & Reems, J. A. (2011). Distinct functional effects for dynamin 3 during megakaryocytopoiesis. Stem Cells and Development, 20(12), 2139–2151. · doi:10.1089/scd.2011.0159
  58. Patel-Hett, S., Wang, H., Begonja, A. J., Thon, J. N., Alden, E. C., Wandersee, N. J., et al. (2011). The spectrin-based membrane skeleton stabilizes mouse megakaryocyte membrane systems and is essential for proplatelet and platelet formation. Blood, 118(6), 1641–1652. · doi:10.1182/blood-2011-01-330688
  59. Dhanjal, T. S., Pendaries, C., Ross, E. A., Larson, M. K., Protty, M. B., Buckley, C. D., et al. (2007). A novel role for PECAM-1 in megakaryocytokinesis and recovery of platelet counts in thrombocytopenic mice. Blood, 109(10), 4237–4244. · doi:10.1182/blood-2006-10-050740
  60. Reddi, A. H., Gay, R., Gay, S., & Miller, E. J. (1977). Transitions in collagen types during matrix-induced cartilage, bone, and bone marrow formation. Proceedings of the National Academy of Sciences of the United States of America, 74(12), 5589–5592. · doi:10.1073/pnas.74.12.5589
  61. Zou, Z., Schmaier, A. A., Cheng, L., Mericko, P., Dickeson, S. K., Stricker, T. P., et al. (2009). Negative regulation of activated alpha-2 integrins during thrombopoiesis. Blood, 113(25), 6428–6439. · doi:10.1182/blood-2008-08-175356
  62. Schachtner, H., Calaminus, S. D., Sinclair, A., Monypenny, J., Blundell, M. P., Leon, C., et al. (2013). Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood, 121(13), 2542–2552. · doi:10.1182/blood-2012-07-443457
  63. Kunert, S., Meyer, I., Fleischhauer, S., Wannack, M., Fiedler, J., Shivdasani, R. A., et al. (2009). The microtubule modulator RanBP10 plays a critical role in regulation of platelet discoid shape and degranulation. Blood, 114(27), 5532–5540. · doi:10.1182/blood-2009-04-216804
  64. Mazhuga, P. M., & Nosova, L. I. (1975). Proliferative characteristics of the endothelial cells and pericytes from the capillary vessels of rabbit bone marrow. Tsitologiia i Genetika, 9(5), 416–419.
  65. Lu, X. G., Zhu, L., Wang, W. Q., Zhang, X. H., Zhao, X. Y., Xu, G. B., et al. (2005). Morphological study on the megakaryocytes with nuclear extrusion and nucleocytoplasmic separation in four cases. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 13(6), 1082–1085.
  66. Hartwig, J. H., & Italiano, J. E., Jr. (2006). Cytoskeletal mechanisms for platelet production. Blood Cells, Molecules & Diseases, 36(2), 99–103. · doi:10.1016/j.bcmd.2005.12.007
  67. Italiano, J. E., Jr., Bergmeier, W., Tiwari, S., Falet, H., Hartwig, J. H., Hoffmeister, K. M., et al. (2003). Mechanisms and implications of platelet discoid shape. Blood, 101(12), 4789–4796. · doi:10.1182/blood-2002-11-3491
  68. Premsler, T., Lewandrowski, U., Sickmann, A., & Zahedi, R. P. (2011). Phosphoproteome analysis of the platelet plasma membrane. Methods in Molecular Biology, 728, 279–290. · doi:10.1007/978-1-61779-068-3_19
  69. Senis, Y., & Garcia, A. (2012). Platelet proteomics: state of the art and future perspective. Methods in Molecular Biology, 788, 367–399. · doi:10.1007/978-1-61779-307-3_24
  70. Parguina, A. F., Rosa, I., & Garcia, A. (2012). Proteomics applied to the study of platelet-related diseases: aiding the discovery of novel platelet biomarkers and drug targets. Journal of Proteomics, 76, 275–286. · doi:10.1016/j.jprot.2012.04.043
  71. Schulz, C., Leuschen, N. V., Frohlich, T., Lorenz, M., Pfeiler, S., Gleissner, C. A., et al. (2010). Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: implications for thrombus formation. Blood, 115(20), 4102–4110. · doi:10.1182/blood-2009-07-230268
  72. Wright, B., Stanley, R. G., Kaiser, W. J., Mills, D. J., & Gibbins, J. M. (2011). Analysis of protein networks in resting and collagen receptor (GPVI)-stimulated platelet sub-proteomes. Proteomics, 11(23), 4588–4592. · doi:10.1002/pmic.201100410
  73. Steinert, B. W., Tang, D. G., Grossi, I. M., Umbarger, L. A., & Honn, K. V. (1993). Studies on the role of platelet eicosanoid metabolism and integrin alpha IIb beta 3 in tumor-cell-induced platelet aggregation. International Journal of Cancer, 54(1), 92–101. · doi:10.1002/ijc.2910540116
  74. Radley, J. M., & Hartshorn, M. A. (1987). Megakaryocyte fragments and the microtubule coil. Blood Cells, 12(3), 603–614.
  75. Escolar, G., Leistikow, E., & White, J. G. (1989). The fate of the open canalicular system in surface and suspension-activated platelets. Blood, 74(6), 1983–1988. · doi:10.1182/blood.v74.6.1983.1983
  76. Cranmer, S. L., Pikovski, I., Mangin, P., Thompson, P. E., Domagala, T., Frazzetto, M., et al. (2005). Identification of a unique filamin A binding region within the cytoplasmic domain of glycoprotein Ibalpha. The Biochemical Journal, 387(Pt 3), 849–858. · doi:10.1042/bj20041836
  77. Mangin, P., David, T., Lavaud, V., Cranmer, S. L., Pikovski, I., Jackson, S. P., et al. (2004). Identification of a novel 14-3-3zeta binding site within the cytoplasmic tail of platelet glycoprotein Ibalpha. Blood, 104(2), 420–427. · doi:10.1182/blood-2003-08-2881
  78. Mu, F. T., Andrews, R. K., Arthur, J. F., Munday, A. D., Cranmer, S. L., Jackson, S. P., et al. (2008). A functional 14-3-3zeta-independent association of PI3-kinase with glycoprotein Ib alpha, the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex. Blood, 111(9), 4580–4587. · doi:10.1182/blood-2007-09-111096
  79. De Caterina, R., Marchetti, P., Bernini, W., Giannarelli, R., Giannessi, D., & Navalesi, R. (1989). The direct effects of metformin on platelet function in vitro. European Journal of Clinical Pharmacology, 37(2), 211–213. · doi:10.1007/bf00558236
  80. Wiwanitkit, V. (2011). Metformin high dosage and bleeding episode: a clinical case study. Indian Journal of Endocrinology and Metabolism, 15(2), 132–133. · doi:10.4103/2230-8210.81947
  81. Harper, M. T., & Poole, A. W. (2013). Chloride channels are necessary for full platelet phosphatidylserine exposure and procoagulant activity. Cell Death and Disease, 4, e969. · doi:10.1038/cddis.2013.495
  82. Tamaru, S., Fukuta, T., Kaibuchi, K., Matsuoka, Y., Shiku, H., & Nishikawa, M. (2005). Rho-kinase induces association of adducin with the cytoskeleton in platelet activation. Biochemical and Biophysical Research Communications, 332(2), 347–351. · doi:10.1016/j.bbrc.2005.04.127
  83. Lind, S. E., Yin, H. L., & Stossel, T. P. (1982). Human platelets contain gelsolin. A regulator of actin filament length. Journal of Clinical Investigation, 69(6), 1384–1387. · doi:10.1172/jci110578
  84. Wang, L. L., & Bryan, J. (1981). Isolation of calcium-dependent platelet proteins that interact with actin. Cell, 25(3), 637–649. · doi:10.1016/0092-8674(81)90171-9
  85. Davidson, M. M., & Haslam, R. J. (1994). Dephosphorylation of cofilin in stimulated platelets: roles for a GTP-binding protein and Ca2+. The Biochemical Journal, 301(Pt 1), 41–47. · doi:10.1042/bj3010041
  86. White, J. G. (1972). Exocytosis of secretory organelles from blood platelets incubated with cationic polypeptides. The American Journal of Pathology, 69(1), 41–54.
  87. White, J. G., & Estensen, R. D. (1972). Degranulation of discoid platelets. The American Journal of Pathology, 68(2), 289–302.
  88. Marks, M. S. (2012). SNARing platelet granule secretion. Blood, 120(12), 2355–2357. · doi:10.1182/blood-2012-07-442756
  89. Fukami, M. H., & Salganicoff, L. (1977). Human platelet storage organelles. A review. Thrombosis and Haemostasis, 38(4), 963–970. · doi:10.1055/s-0038-1651914
  90. Emiliani, C., Martino, S., Orlacchio, A., Vezza, R., Nenci, G. G., & Gresele, P. (1995). Platelet glycohydrolase activities: characterization and release. Cell Biochemistry and Function, 13(1), 31–39. · doi:10.1002/cbf.290130108
  91. Gordon, J. L. (1975). Blood platelet lysosomes and their contribution to the pathophysiological role of platelets. Frontiers of Biology, 43(4), 3–31.
  92. Metzelaar, M. J., & Clevers, H. C. (1992). Lysosomal membrane glycoproteins in platelets. Thrombosis and Haemostasis, 68(4), 378–382. · doi:10.1055/s-0038-1646280
  93. Waite, M., & Griffin, H. D. (1976). The phospholipases A of lysosomes. Frontiers of Biology, 45, 257–305.
  94. Sabetkar, M., Naseem, K. M., Tullett, J. M., Friebe, A., Koesling, D., & Bruckdorfer, K. R. (2001). Synergism between nitric oxide and hydrogen peroxide in the inhibition of platelet function: the roles of soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein. Nitric Oxide, 5(3), 233–242. · doi:10.1006/niox.2001.0343
  95. Dutta-Roy, A. K., & Sinha, A. K. (1987). Purification and properties of prostaglandin E1/prostacyclin receptor of human blood platelets. The Journal of Biological Chemistry, 262(26), 12685–12691. · doi:10.1016/s0021-9258(18)45261-1
  96. Dittrich, M., Birschmann, I., Mietner, S., Sickmann, A., Walter, U., & Dandekar, T. (2008). Platelet protein interactions: map, signaling components, and phosphorylation groundstate. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(7), 1326–1331. · doi:10.1161/atvbaha.107.161000
  97. Yamanaka, M., Kume, S., Kariya, T., & Tanabe, A. (1979). cAMP-dependent protein kinase in human platelets and effect of prostaglandin E1 on its endogenous substrates (author’s transl). Nihon Ketsueki Gakkai Zasshi, 42(3), 541–542.
  98. Sand, C., Grandoch, M., Borgermann, C., Oude Weernink, P. A., Mahlke, Y., Schwindenhammer, B., et al. (2010). 8-pCPT-conjugated cyclic AMP analogs exert thromboxane receptor antagonistic properties. Thrombosis and Haemostasis, 103(3), 662–678. · doi:10.1160/th09-06-0341
  99. Siess, W., Winegar, D. A., & Lapetina, E. G. (1990). Rap1-B is phosphorylated by protein kinase A in intact human platelets. Biochemical and Biophysical Research Communications, 170(2), 944–950. · doi:10.1016/0006-291x(90)92182-y
  100. Marquis, N. R., Vigdahl, R. L., & Tavormina, P. A. (1969). Platelet aggregation. I. Regulation by cyclic AMP and prostaglandin E1. Biochemical and Biophysical Research Communications, 36(6), 965–972. · doi:10.1016/0006-291x(69)90298-8
  101. Salzman, E. W. (1967). ADP-platelet aggregation. Thrombosis et Diathesis Haemorrhagica. Supplementum, 26, 197–199.
  102. Brodie, G. N., Baenziger, N. L., Chase, L. R., & Majerus, P. W. (1972). The effects of thrombin on adenyl cyclase activity and a membrane protein from human platelets. The Journal of Clinical Investigation, 51(1), 81–88. · doi:10.1172/jci106800
  103. Watanabe, N. (2010). RIAM: bridge between Rap1 and integrin. Rinshō Ketsueki, 51(6), 377–383.
  104. Huang, J. S., Dong, L., Kozasa, T., & Le Breton, G. C. (2007). Signaling through G(alpha)13 switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion. The Journal of Biological Chemistry, 282(14), 10210–10222. · doi:10.1074/jbc.m605678200
  105. Itoh, K., Hara, T., & Shibata, N. (1992). Diphosphorylation of platelet myosin by myosin light chain kinase. Biochimica et Biophysica Acta, 1133(3), 286–292. · doi:10.1016/0167-4889(92)90049-h
  106. Coburn, L. A., Damaraju, V. S., Dozic, S., Eskin, S. G., Cruz, M. A., & McIntire, L. V. (2011). GPIbalpha-vWF rolling under shear stress shows differences between type 2B and 2M von Willebrand disease. Biophysical Journal, 100(2), 304–312. · doi:10.1016/j.bpj.2010.11.084
  107. Colace, T. V., & Diamond, S. L. (2013). Direct observation of von Willebrand factor elongation and fiber formation on collagen during acute whole blood exposure to pathological flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(1), 105–113. · doi:10.1161/atvbaha.112.300522
  108. Clemetson, K. J. (2007). A short history of platelet glycoprotein Ib complex. Thrombosis and Haemostasis, 98(1), 63–68.
  109. Bernard, J., & Soulier, J. (1948). Sur une nouvelle variété de dystrophie thrombocytaire-hémorragipare congénitale. Semin Hôp Paris, 24, 3217–3223.
  110. Gardiner, E. E., Arthur, J. F., Berndt, M. C., & Andrews, R. K. (2005). Role of calmodulin in platelet receptor function. Current Medicinal Chemistry. Cardiovascular and Hematological Agents, 3(4), 283–287. · doi:10.2174/156801605774322283
  111. De Ceunynck, K., De Meyer, S. F., & Vanhoorelbeke, K. (2013). Unwinding the von Willebrand factor strings puzzle. Blood, 121(2), 270–277. · doi:10.1182/blood-2012-07-442285
  112. Nurden, A. T., & Caen, J. P. (1974). An abnormal platelet glycoprotein pattern in three cases of Glanzmann’s thrombasthenia. British Journal of Haematology, 28(2), 253–260. · doi:10.1111/j.1365-2141.1974.tb06660.x
  113. Phillips, D. R., Jenkins, C. S., Luscher, E. F., & Larrieu, M. (1975). Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature, 257(5527), 599–600. · doi:10.1038/257599a0
  114. Glanzmann, E. (1918). Hereditare hammorhagische thrombastehnie. Beitr Pathologie Bluplatchen J Kinderkt, 88, 113–141.
  115. Clemetson, K. J. (1995). Platelet activation: signal transduction via membrane receptors. Thrombosis and Haemostasis, 74(1), 111–116. · doi:10.1055/s-0038-1642662
  116. Asselin, J., Knight, C. G., Farndale, R. W., Barnes, M. J., & Watson, S. P. (1999). Monomeric (glycine-proline-hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. The Biochemical Journal, 339(Pt 2), 413–418. · doi:10.1042/0264-6021:3390413
  117. Zahid, M., Mangin, P., Loyau, S., Hechler, B., Billiald, P., Gachet, C., et al. (2012). The future of glycoprotein VI as an antithrombotic target. Journal of Thrombosis and Haemostasis, 10(12), 2418–2427. · doi:10.1111/jth.12009
  118. Ordonez, N. G. (2013). Value of podoplanin as an immunohistochemical marker in tumor diagnosis: a review and update. Applied Immunohistochemistry & Molecular Morphology.
  119. Watson, A. A., & O'Callaghan, C. A. (2005). Crystallization and X-ray diffraction analysis of human CLEC-2. Acta Crystallographica. Section F, Structural Biology and Crystallization Communications, 61(Pt 12), 1094–1096. · doi:10.1107/s1744309105037991
  120. Suzuki-Inoue, K., Inoue, O., & Ozaki, Y. (2011). The novel platelet activation receptor CLEC-2. Platelets, 22(5), 380–384. · doi:10.3109/09537104.2011.556274
  121. Zimmermann, H. (1999). Nucleotides and cd39: principal modulatory players in hemostasis and thrombosis. Nature Medicine, 5(9), 987–988. · doi:10.1038/12419
  122. Nathan, P. (1973). The migration of human platelets in vitro. Thrombosis et Diathesis Haemorrhagica, 30(1), 173–177.
  123. Brown, P. (2005). Lymphatic system: unlocking the drains. Nature, 436(7050), 456–458. · doi:10.1038/436456a
  124. Bouvenot, G., Escande, M., Xeridat, B., Simonin, G., Boucoiran, J., & Delboy, C. (1977). Thrombocytosis and cancer. Apropos of a chronological series of 100 patients. La Semaine des Hôpitaux, 53(36), 1921–1925.
  125. Rank, A., Liebhardt, S., Zwirner, J., Burges, A., Nieuwland, R., & Toth, B. (2012). Circulating microparticles in patients with benign and malignant ovarian tumors. Anticancer Research, 32(5), 2009–2014.
  126. van Doormaal, F., Kleinjan, A., Berckmans, R. J., Mackman, N., Manly, D., Kamphuisen, P. W., et al. (2012). Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thrombosis and Haemostasis, 108(1), 160–165. · doi:10.1160/th12-02-0099
  127. Rank, A., Nieuwland, R., Roesner, S., Nikolajek, K., Hiller, E., & Toth, B. (2012). Climacteric lowers plasma levels of platelet-derived microparticles: a pilot study in pre- versus postmenopausal women. Acta Haematologica, 128(1), 53–59. · doi:10.1159/000337327
  128. Green, D. L., & Karpatkin, S. (2009). Effect of cancer on platelets. Cancer Treatment and Research, 148, 17–30. · doi:10.1007/978-0-387-79962-9_2
  129. Grignani, G., Pacchiarini, L., Almasio, P., Pagliarino, M., Gamba, G., Rizzo, S. C., et al. (1986). Characterization of the platelet-aggregating activity of cancer cells with different metastatic potential. International Journal of Cancer, 38(2), 237–244. · doi:10.1002/ijc.2910380214
  130. Pacchiarini, L., Zucchella, M., Milanesi, G., Tacconi, F., Bonomi, E., Canevari, A., et al. (1991). Thromboxane production by platelets during tumor cell-induced platelet activation. Invasion & Metastasis, 11(2), 102–109.
  131. Tzanakakis, G. N., Krambovitis, E., Tsatsakis, A. M., & Vezeridis, M. P. (2002). The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. International Journal of Gastrointestinal Cancer, 32(1), 23–30. · doi:10.1385/ijgc:32:1:23
  132. Gordon, S. G., & Chelladurai, M. (1992). Non-tissue factor procoagulants in cancer cells. Cancer Metastasis Reviews, 11(3–4), 267–282. · doi:10.1007/bf01307182
  133. Kirwan, C. C., McDowell, G., McCollum, C. N., Kumar, S., & Byrne, G. J. (2008). Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. British Journal of Cancer, 99(7), 1000–1006. · doi:10.1038/sj.bjc.6604620
  134. Starakis, I., Koutras, A., & Mazokopakis, E. E. (2010). Drug-induced thromboembolic events in patients with malignancy. Cardiovascular & Hematological Disorders Drug Targets, 10(2), 94–102. · doi:10.2174/187152910791292493
  135. Anand, M., & Brat, D. J. (2012). Oncogenic regulation of tissue factor and thrombosis in cancer. Thrombosis Research, 129(Suppl 1), S46–49. · doi:10.1016/s0049-3848(12)70015-4
  136. Ogiichi, T., Hirashima, Y., Nakamura, S., Endo, S., Kurimoto, M., & Takaku, A. (2000). Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. Journal of Neuro-Oncology, 46(1), 1–9. · doi:10.1023/a:1006323200001
  137. Jurasz, P., North, S., Venner, P., & Radomski, M. W. (2003). Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study. Thrombosis Research, 112(1–2), 59–64. · doi:10.1016/j.thromres.2003.10.012
  138. Lindenmeyer, F., Legrand, Y., & Menashi, S. (1997). Upregulation of MMP-9 expression in MDA-MB231 tumor cells by platelet granular membrane. FEBS Letters, 418(1–2), 19–22. · doi:10.1016/s0014-5793(97)01336-7
  139. Oleksowicz, L., Mrowiec, Z., Schwartz, E., Khorshidi, M., Dutcher, J. P., & Puszkin, E. (1995). Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thrombosis Research, 79(3), 261–274. · doi:10.1016/0049-3848(95)00113-6
  140. Timar, J., Trikha, M., Szekeres, K., Bazaz, R., & Honn, K. (1998). Expression and function of the high affinity alphaIIbbeta3 integrin in murine melanoma cells. Clinical & Experimental Metastasis, 16(5), 437–445. · doi:10.1023/a:1006533508560
  141. Trikha, M., Timar, J., Lundy, S. K., Szekeres, K., Cai, Y., Porter, A. T., et al. (1997). The high affinity alphaIIb beta3 integrin is involved in invasion of human melanoma cells. Cancer Research, 57(12), 2522–2528.
  142. Iwamura, T., Caffrey, T. C., Kitamura, N., Yamanari, H., Setoguchi, T., & Hollingsworth, M. A. (1997). P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Cancer Research, 57(6), 1206–1212.
  143. Goschnick, M. W., & Jackson, D. E. (2007). Tetraspanins-structural and signalling scaffolds that regulate platelet function. Mini Reviews in Medicinal Chemistry, 7(12), 1248–1254. · doi:10.2174/138955707782795656
  144. Billroth, T. (1878). Lectures on surgical pathology and therapeutics, a handbook for students and practitioners (vol. II). London: The New Sydenham Society.
  145. Baserga, R., & Saffiotti, U. (1955). Experimental studies on histogenesis of blood-borne metastases. AMA Archives of Pathology, 59(1), 26–34.
  146. Chew, E. C., & Wallace, A. C. (1976). Demonstration of fibrin in early stages of experimental metastases. Cancer Research, 36(6), 1904–1909.
  147. Warren, B. A. (1976). Some aspects of blood borne tumour emboli associated with thrombosis. Zeitschrift für Krebsforschung und Klinische Onkologie. Cancer Research and Clinical Oncology, 87(1), 1–15.
  148. Oleksowicz, L., & Dutcher, J. P. (1995). Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies. Medical Oncology, 12(2), 95–102. · doi:10.1007/bf01676709
  149. Lonsdorf, A. S., Kramer, B. F., Fahrleitner, M., Schonberger, T., Gnerlich, S., Ring, S., et al. (2012). Engagement of alphaIIbbeta3 (GPIIb/IIIa) with alphanubeta3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. The Journal of Biological Chemistry, 287(3), 2168–2178. · doi:10.1074/jbc.m111.269811
  150. Beleva, E., & Grudeva-Popova, J. (2013). From Virchow’s triad to metastasis: circulating hemostatic factors as predictors of risk for metastasis in solid tumors. Journal of BUON, 18(1), 25–33.
  151. Jafari, S., Etminan, M., & Afshar, K. (2009). Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Canadian Urological Association Journal, 3(4), 323–330. · doi:10.5489/cuaj.1129
  152. Chan, A. T., Zauber, A. G., Hsu, M., Breazna, A., Hunter, D. J., Rosenstein, R. B., et al. (2009). Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. doi: 10.1053/j.gastro.2009.02.045 . · doi:10.1053/j.gastro.2009.02.045

Cited by

See all 316

Metadata

Authors
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V.
Venue
Cancer and Metastasis Reviews
Published
2014-03
Volume
33
Issue
1
Pages
231-269
ISSN
  • 0167-7659 (ISSN-L)
  • 1573-7233
OpenAlex
W2079629625
Cited by
316
References
389
FWCI
3.24
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Platelets and cancer: a casual or causal relationship: revisited. https://app.cochat.ai/papers/10.1007/s10555-014-9498-0
The paper
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014). Platelets and cancer: a casual or causal relationship: revisited. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-014-9498-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.